HEALTH OF WOMAN.2016.7(113):11–15; doi 10.15574/HW.2016.113.11 
 

Nonsteroidal anti-inflammatory drugs: certain aspects of the use in obstetric clinic 
 

Nazarenko L. H.

Kharkiv medical Academy of postgraduate education

The article discusses the pathogenetic basis of a nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical medicine. Presented classification and list registered in Ukraine representatives of this group of drugs. Posted current understanding of the mechanisms of clinical efficacy of NSAIDs and side effects. Presented the information about the place NSPVP during pregnancy, risks to the fetus, positive aspects in the management of women with threatened preterm labor, pathological preliminary period, as well as a basic component of postoperative pain management after obstetric and gynecological operations.

Key words: nonsteroidal anti-inflammatory drug, premature birth, preliminary period, postoperative analgesia.

REFERENCES

1. Nasonov EL.2000. Nesteroidnyie protivovospalitelnyie preparatyi (Perspektivyi primeneniya v meditsine). M, Izd-vo Anko:143.

2. Abramchenko VV, Proshyan AP. 2005. Nesteroidnyie protivovospalitelnyie sredstva v akusherstve i ginekologii. SPb, Elbi:316.

3. Hernandez RK, Werler MM, Romitti P et al. 2012. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am. J. Obstet.Gynecol. 206:228.e1-8. http://dx.doi.org/10.1016/j.ajog.2011.11.019; PMid:22196851

4. Marsh CA, Cragan JD, Alverson CJ et al. 2014. Case-control analysis of maternal prenatal analgesic use and cardiovascular malformations: Baltimore–Washington Infant Study Courtney. Am. J. Obstet. Gynecol. 211;4:404.e1–404.e9 http://dx.doi.org/10.1016/j.ajog.2014.03.054; PMid:24681289 PMCid:PMC4406339

5. Atad J, David A, Moise J, Abramovici H. 1980. Classification of threatened premature labor related to treatment with a prostaglandin inhibitor: indomethacin. Biol. Neonate. 37:291–296. http://dx.doi.org/10.1159/000241289; PMid:7388083

6. Stika CS, Gross GA, Leguizamon G et al. 2002. A prospective randomized safety trial of celecoxib for treatment of preterm labor. 187;3:653–660. http://dx.doi.org/10.1067/mob.2002.125281

7. Hernandez RK, Werler MM, Romitti P et al. 2012. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am. J. Obstet. Gynecol. 206;3:228.e1–228.e8. http://dx.doi.org/10.1016/j.ajog.2011.11.019; PMid:22196851

8. Bivins HA Jr, Newman RB, Fyfe DA et al. 1993. Randomized comparative trial of indomethacin and terbutaline forthe long term treatment of preterm labor. Am. J. Obstet. Gynecol. 168:375. http://dx.doi.org/10.1016/S0002-9378(12)90690-0

9. Cabrol D, Landesman R, Muller J et al. 1987. Treatment of polyhydramnios with prostaglandin synthetase inhibitor (indomethacin). Am. J. Obstet. Gynecol. 157:422–426. http://dx.doi.org/10.1016/S0002-9378(87)80185-0

10. Hammers AL, Sanchez-Ramos L, Kaunitz AM. 2015. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. Am. J. Obstet. Gynecol. 212;4:505.e1–505.e13. http://dx.doi.org/10.1016/j.ajog.2014.10.1091; PMid:25448524

11. De Wit W, Van Mourik I, Wiesenhaan PF. 1988. Prolonged maternal indomethacin therapy associated with oligohydramnios: case reports. Br. J. Obstet. Gynecol. 95:303–305. http://dx.doi.org/10.1111/j.1471-0528.1988.tb06874.x

12. Kirshon B, Mari G, Moise KJ Jr. 1990. Indomethacin therapy in the treatment of symptomatic polyhydramnios. Obstet. Gynecol. 75:202–205. PMid:2405320

13. Refuerzo J. 2015. Liposomes a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model. Am. J. Obstet. Gynecol. 212:508.e1-7. http://dx.doi.org/10.1016/j.ajog.2014.10.100; http://dx.doi.org/10.1016/j.ajog.2015.02.006; PMid:25683966

14. Rac VE, Small K, Scott CA et al. 2006, Aug. Meloxicam effectively inhibits preterm labor uterine contractions in a chronically catheterized pregnant sheep model: Impact on fetal blood flow and fetal-maternal physiologic parameters. Am. J. Obstet. Gynecol. 195;2:528–534. http://dx.doi.org/10.1016/j.ajog.2006.02.011; PMid:16626612

15. Proshyan AP. 2006. Kliniko-eksperimentalnaya otsenka effektivnosti nesteroidnyih protivovospalitelnyih preparatov v terapii patologicheskogo preliminarnogo perioda. Diss. kand. med. nauk. 14.00.01. Akusherstvo i ginekologiya. Sankt-Peterburg.

16. McCormack K, Brune K. 1991. Dissociation between the antinociceptive and antiinflammatory effects of the non-steroidal antiinfammatory drugs. Drugs 41:533–547. http://dx.doi.org/10.2165/00003495-199141040-00003; PMid:1711958

17. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM. 2010. Acute Pain Management: Scientific Evidence (3rd edition) Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine, ANZCA & FPM, Melbourne. http://www.anzca.edu.au/resources/books-and-publications/

18. Amy M, Pick AM, DeSimone EM. 2010. The Management of Acute Postoperative Pain. US Pharm. 35(5):HS-2-HS-7.

19. Kobelyatskiy YuYu. 2010. NPVP v posleoperatsionnom obezbolivanii: effektivnost i bezopasnost s pozitsii dokazatelnoy meditsinyi. Zdorov’e Ukrainy 3:26–27.